Recent Scares Could Impede Chinese Generic Exports To U.S.
This article was originally published in PharmAsia News
Executive Summary
In light of the recent scare involving Chinese-produced heparin and other safety issues, the budding generics drug industry in China could face a tough sell in the United States. The head of the American drug standards-setting organization, U.S. Pharmacopeia, said the recent product-safety incidents should be of concern to U.S. regulators. But he and another pharmaceutical market expert noted China has the people with skills and drive to comply with good manufacturing practices, enough so to make them a dominant generics marketer to the United States. (Click here for more